Ilaria Testi1, Aniruddha Agarwal2, Rupesh Agrawal3, Sarakshi Mahajan4, Alessandro Marchese5, Elisabetta Miserocchi5, Vishali Gupta2. 1. Medical Retina and Uveitis Service, Moorfields Eye Hospital, NHS Foundation Trust , London, UK. 2. Department of Ophthalmology, Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh, India. 3. Department of Ophthalmology, National Health Care Group Eye Institute, Tan Tock Seng Hospital , Singapore. 4. School of Medicine, St Joseph Mercy Hospital , Oakland Pontiac, Michigan. 5. Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute San Raffaele , Milan, Italy.
Abstract
Purpose: To describe drug-induced uveitis in immunocompromised patients diagnosed with Human Immunodeficiency Virus (HIV) infection Methods: Narrative Review Results: Systemic and intraocular medications administered for the treatment of acquired immune deficiency syndrome (AIDS)-associated diseases in patients infected with HIV are a well-known cause of uveitis. Conclusions: Cidofovir and rifabutin, among other novel anti-retroviral therapies, are strongly associated with drug-induced uveitis. It is imperative to understand the pathogenesis, clinical findings, and management of HIV patients with uveitis induced by these agents.
Purpose: To describe drug-induced uveitis in immunocompromised patients diagnosed with Human Immunodeficiency Virus (HIV) infection Methods: Narrative Review Results: Systemic and intraocular medications administered for the treatment of acquired immune deficiency syndrome (AIDS)-associated diseases in patients infected with HIV are a well-known cause of uveitis. Conclusions: Cidofovir and rifabutin, among other novel anti-retroviral therapies, are strongly associated with drug-induced uveitis. It is imperative to understand the pathogenesis, clinical findings, and management of HIVpatients with uveitis induced by these agents.
Authors: L De Simone; M Bonacini; S Croci; L Cimino; R Aldigeri; F Alessandrello; V Mastrofilippo; F Gozzi; E Bolletta; C Adani; A Zerbini; G M Cavallini; L Fontana; C Salvarani Journal: Inflamm Res Date: 2022-06-28 Impact factor: 6.986